The SOUL trial showed that oral semaglutide was safe in patients with type 2 diabetes and atherosclerotic cardiovascular ...

Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly ...

Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of ...

A global trial finds Wegovy and Ozempic significantly improve liver health in patients and treats those with advanced fatty ...

Nearly twice as many people taking semaglutide stopped their fatty liver disease without further scarring of the organ, ...

Wegovy (semaglutide) could offer a new option to treat severe liver disease based on new clinical trial evidence. The GLP-1 ...

A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...

FAT jabs can treat a liver disease affecting one in five people, a trial found. Semaglutide cut inflammation in two thirds of ...

Findings showed a 13.6% reduction in body weight in the semaglutide 25mg group compared with a 2.2% reduction in the placebo group.

Prior to starting the trial, the participants also had moderate to high levels of scar tissue in the liver, known as stage 2 ...